Mertsching Heike, Schanz Johanna, Steger Volker, Schandar Markus, Schenk Martin, Hansmann Jan, Dally Iris, Friedel Godehard, Walles Thorsten
Fraunhofer Institute for Interfacial Engineering and Biotechnology, Department Cellsystems, Stuttgart, Germany.
Transplantation. 2009 Jul 27;88(2):203-10. doi: 10.1097/TP.0b013e3181ac15e1.
The lack of transplant vascularization forecloses the generation and clinical implementation of bioartificial tissues. We developed techniques to generate a bioartificial human tissue with an innate vascularization. The tissue was implanted clinically as proof of concept to evaluate vascular network thrombogenicity and tissue viability after transplantation.
A porcine small bowl segment was decellularized in a two-step procedure, preserving its vascular structures. The extracellular matrix was characterized quantitatively for DNA residues and protein composition. The vascular remainings were reseeded with human endothelial cells in a dynamic tissue culture. The engineered tissue was characterized by (1) histology, (2) immune-histology, (3) life-dead assay, and (4) metabolic activity. To evaluate the tissue capabilities, it was implanted clinically and recovered after 1 week.
Tissue preparation with sodium desoxycholate monohydrate solution resulted in an incomplete decellularization. Cell residues were removed by additional tissue incubation with DNAse. The human endothelial cells formed a viable endothelium inside the primarily porcine extracellular matrix, expressing CD31, Flk-1, and vascular endothelium-cadherin. The metabolic activity of the bioartificial tissue increased continuously over time in vitro. Clinical tissue transplantation confirmed vessel patency and tissue viability for 1 week.
The feasibility to bioengineer a human tissue with an innate vascularization has been shown in vitro and the clinical setting. These results may open the door for the clinical application of various sophisticated bioartificial tissue substitutes and organ replacements.
移植血管化的缺失阻碍了生物人工组织的生成及临床应用。我们开发了生成具有固有血管化的生物人工人体组织的技术。该组织被临床植入以作为概念验证,用于评估移植后血管网络的血栓形成性和组织活力。
采用两步法对猪小肠段进行脱细胞处理,保留其血管结构。对细胞外基质进行DNA残留和蛋白质组成的定量分析。在动态组织培养中用人内皮细胞重新接种血管残留物。通过(1)组织学、(2)免疫组织学、(3)死活测定和(4)代谢活性对工程组织进行表征。为评估该组织的性能,将其临床植入并在1周后取出。
用一水脱氧胆酸钠溶液进行组织制备导致脱细胞不完全。通过用DNA酶对组织进行额外孵育去除细胞残留。人内皮细胞在主要为猪的细胞外基质内形成了有活力的内皮,表达CD31、Flk-1和血管内皮钙黏蛋白。生物人工组织的代谢活性在体外随时间持续增加。临床组织移植证实血管通畅且组织活力维持了1周。
在体外和临床环境中已证明生物工程构建具有固有血管化的人体组织的可行性。这些结果可能为各种复杂的生物人工组织替代物和器官替换的临床应用打开大门。